Because genetic, antibody or decoy receptor mediated inhibition of myostatin reverses cachexia in mice with different diseases and because cachexia in chronic disease is associated with a particularly poor prognosis in humans [6,14-18], therapeutic strategies to inhibit myostatin signalling in patients are being developed [19]. The gene discussed is MSTN; the disease is Cachexia.